Related Experiment Videos
[Pseudomyxoma peritonei]
C H Dejong1, M H Booster, P H Theunissen
1Afd. Algemene Heelkunde, De Wever Ziekenhuis, Heerlen.
Abstract:
Pseudomyxoma peritonei was diagnosed in 3 men aged 38, 66 and 54 years with weight loss and distension of the abdomen. Pseudomyxoma peritonei results from seeding of the peritoneal cavity with mucus-producing epithelium. The disease is traditionally characterized by accumulation of huge amounts of mucinous ascites, relatively long survival and absence of distant, extraperitoneal metastases. Mostly, the primary tumour is an appendicular adenoma or adenocarcinoma. Sometimes, the primary tumor is localized in the ovaries. Extensive surgical debulking with postoperative intraperitoneal chemotherapy appears to be the treatment of choice.
Insights
Pseudomyxoma peritonei, a rare condition causing abdominal distension, was diagnosed in three men. Treatment involves surgical debulking and chemotherapy.
Area of Science:
- Gastroenterology
- Oncology
Background:
- Pseudomyxoma peritonei (PMP) arises from mucinous epithelium seeding within the peritoneal cavity.
- Characterized by extensive mucinous ascites, PMP typically presents with prolonged survival and no distant metastases.
Observation:
- Three male patients aged 38, 66, and 54 presented with weight loss and abdominal distension.
- Clinical presentation indicated the presence of pseudomyxoma peritonei.
Findings:
- The primary tumors are most commonly appendiceal adenomas or adenocarcinomas.
- Ovarian tumors can also be the primary source of PMP.
Implications:
- Surgical debulking combined with postoperative intraperitoneal chemotherapy is the recommended treatment strategy.
- Early diagnosis and tailored treatment are crucial for managing PMP effectively.